Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.


Women and Diabetes: Preventing Heart Disease in a New Era of Therapies


21 October 2021


European Cardiology Review 2021;16:e40.

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction


European Cardiology Review 2020;15:e32.

Evaluation of the Effect of Heart Failure Reversal Therapy on Anthropometric Obesity Parameters in Patients with Chronic Heart Failure: A Retrospective Analysis


European Cardiology Review 2020;15:e37.

Evaluation of the Effect of Heart Failure Reversal Therapy on Exercise Capacity in Patients with Chronic Heart Failure and the Association with Co-morbidities


European Cardiology Review 2020;15:e39.